Interventional Cardiology Devices Market

The global interventional cardiology devices market is projected to reach USD 42.39 billion by 2031, from USD 31.12 billion in 2026, growing at a CAGR of 6.4% during the forecast period.

The global interventional cardiology devices market is primarily driven by the rising prevalence of cardiovascular diseases, including coronary artery disease, heart failure, and structural heart disorders, which are increasing globally, especially among aging populations with sedentary lifestyles and amid rising rates of diabetes and obesity. The growing preference for interventional cardiology devices in the operating room is also driving market expansion. These procedures are associated with shorter hospital stays, faster recovery, and lower complication rates. Continuous technological advancements, such as drug-eluting stents, bioresorbable scaffolds, transcatheter heart valves, and improved imaging and navigation systems, are increasing procedural success and expanding the range of treatments offered. Additionally, growing healthcare expenditure for better access to high-tech cancer pain management in underdeveloped countries and the increasing number of catheterization labs being set up are major factors driving market growth. Furthermore, expanding reimbursement policies in developed countries and the growing need for early diagnosis and interventional treatment of cardiovascular conditions help maintain the global interventional cardiology devices market's growth.

To know about the assumptions considered for the study download the pdf brochure

• In March 2025, Boston Scientific Corporation announced it had entered into a definitive agreement to acquire SoniV0ie Ltd., a privately held medical device company that has developed the TIVUS Intravascular Ultrasound System. The TIVUS system is an investigational technology designed to denervate nerves surrounding blood vessels to treat a variety of hypertensive disorders, including renal artery denervation (RDN) for hypertension.

• In February 2025, Teleflex Incorporated, a leading global provider of medical technologies, announced that it had entered into a definitive agreement to acquire substantially all of the Vascular Intervention business of BIOTRONIK SE & Co. KG for an estimated price at closing of approximately USD 887 million.

The prominent players operating in the interventional cardiology devices market are Boston Scientific Corporation (US), Medtronic (US), Abbott (US), B. Braun SE (Germany), Terumo Corporation (Japan), Edwards Lifesciences Corporation (US), Koninklijke Philips N.V. (Netherlands), Integer Holdings Corporation (US), Teleflex Incorporated (US), Penumbra, Inc. (US), Cook (US), Cordis (US), iVascular S.L.U (Spain), Biosensors International Group, Ltd (Singapore), BIOTRONIK SE & Co. KG (Germany).

Edwards Lifesciences Corporation. (US):

Edwards Lifesciences’ leadership in aortic heart valve replacement, among other areas, has been a significant factor in its position as the most powerful player in the global interventional cardiology devices market. Additionally, the company’s dedication to research and development has been a major driver of its success in developing worldwide interventions, even for critical patient populations, through advanced technologies and improved delivery systems. Through large-scale studies that provide long-term outcome data, Edwards has a strong foundation of clinical evidence that supports regulatory approvals and reimbursement worldwide. The company’s well-established global manufacturing and distribution network also ensures that its products are available in every part of the world and that there are no delays in availability in developed and emerging markets. Through strategic acquisitions, technology partnerships, and targeted portfolio expansion in hemodynamic monitoring and advanced imaging-enabled interventions, Edwards Lifesciences has maintained its competitive edge and, consequently, its growth in the global interventional cardiology devices market.

Medtronic (US):

Medtronic is a well-known brand in the global interventional cardiology devices market. It is well-positioned to maintain its standing due to its extensive and varied product line, which includes coronary stents, drug-eluting technologies, atherectomy and thrombectomy systems, and structural heart devices such as transcatheter mitral and tricuspid repair systems. The company’s steadfast commitment to R&D and innovation enables the timely introduction of next-generation platforms that improve deliverability, clinical performance, and long-term patient outcomes. Medtronic’s wide-reaching global presence and manufacturing capacity ensure that its technologies are available in large quantities across both developed and developing regions, further supported by strong physician relationships and educational programs that promote the use of advanced interventional therapies. Through strategic M&A deals and partnerships, for example, imaging-enhanced guidance systems or device technologies, Medtronic not only gains a competitive advantage but also expands its target market. In addition, Medtronic benefits from a robust clinical evidence base generated through landmark clinical trials and comprehensive regulatory programs. A mix of innovation, global reach, clinical credibility, and strategic growth powers Medtronic’s sustained presence in the interventional cardiology devices market.

Boston Scientific Corporation (US)

Boston Scientific holds a leading position in the global interventional cardiology devices market due to its extensive, technologically advanced portfolio covering coronary, peripheral, and structural heart interventions. The company’s continuous innovation drive, especially in next-generation drug-eluting stents, specialty balloon catheters, atherectomy systems, and intravascular imaging-guided tools, addresses the most demanding clinical needs and the most intricate procedural challenges. Heavy investment in R&D enables Boston Scientific to launch a range of solutions that not only boost effectiveness but also enhance procedural quality and overall workflow, reinforcing the growing acceptance among doctors worldwide. Strategic capacity expansion and manufacturing upgrades strengthen the supply chain and improve access to the global market. In addition, through continuous collaborations, partnerships, and selective acquisitions (such as integrating emerging technologies into renal denervation and advanced imaging), the company not only expands its technology base and clinical reach but also advances existing technologies to the next level. Moreover, the firm’s worldwide distribution network and strong ties with health care providers enable rapid market penetration in both developed and emerging markets, supported by a growing number of clinical studies demonstrating the safety and efficacy of the products. Together, these factors drive Boston Scientific's competitive edge and continue to fuel its growth in the global interventional cardiology devices market.

Market Ranking

The global market for interventional cardiology devices is moderately to highly concentrated, with a few multinational companies commanding a large share of the total market. Edwards Lifesciences is the dominant player in the interventional cardiology market, driven by its advanced treatments for transcatheter structural heart therapies, including transcatheter aortic valve implantation and transcatheter mitral valve repair. Despite limited exposure to coronary interventions, Edwards' clinical evidence, continuous innovation, and widespread acceptance in advanced cardiac centers contribute to its leadership. Medtronic is another dominant player in the market; it has a wide and varied cardiovascular portfolio, including coronary, peripheral, and structural heart interventions, and also provides technologies for procedural guidance and adjuncts. In addition, the scale of global manufacturing, established hospital and clinician relationships, and investment in next-generation interventional platforms underpin its competitive advantage. Boston Scientific is another player in the market, particularly active in complex coronary and peripheral interventions, with a comprehensive product portfolio that includes drug-eluting stents, balloon catheters, atherectomy systems, intravascular lithotripsy, and a growing structural heart franchise. Boston Scientific's presence in the global interventional cardiology devices market is marked by strong clinical support, a steady stream of innovations, and broad penetration across catheterization laboratories worldwide.

Related Reports:

Interventional Cardiology Devices Market by Type [Stents (Drug-eluting Stent, Bare Metal Stent), Catheters (Angiography, Guiding, IVUS/OCT Catheter), Balloons, Plaque Modification Devices, Hemodynamic Flow Alteration], End User-Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com